Crowd_gfk.png
Crowd-man_gfk.png
Crowd-boy_gfk.png
Crowd-woman_gfk.png

 Existing cell therapies have known limitations, including manufacturing challenges and difficulty targeting solid tumors. The ATAK platform overcomes these limitations.

Key Platform Characteristics

CD14_line_edited_edited_edited_edited_ed
Woman_silhouette_Platform_center.png

Harnessing the frequent migration of myeloid cells from the blood into solid tumors as well as sites of inflammation

cell_antitumorIcon2.png

Empowering myeloid cells to produce anti-tumor agents and modify the tumor microenvironment

Directing phagocytic properties of myeloid cells, including the capability to recognize and engulf cancer cells

CancerCellCluster.png
Phagocyte.png
Phagocyte.png
Phagocyte.png

Bridging innate and adaptive immunity, to elicit a broad anti-tumor immune response with tumor specific T cells

T-cell.png
T-cell.png
T-cell.png
CD14_line_edited_edited_edited_edited_ed
 

ATAK™ Immunotherapy Platform 

Myeloid’s proprietary ATAK platform is designed to harness the innate abilities of myeloid cells.  When applied to a therapeutic candidate, the immunotherapy is designed to recognize cancer cells, produce anti-tumor agents, promote anti-tumor adaptive immunity, alter the tumor microenvironment, and ultimately to kill cancer. Myeloid is currently focused on advancing its ATAK CAR monocytes, which are myeloid cells with innate immune receptor-inspired CARs to recognize and kill cancer.  

In addition, Myeloid has streamlined its manufacturing for its ATAK cell therapy candidates through a rapid, single-day cell process, which provides significant advantages to the patient and contract development and manufacturing organizations (CDMO) over allogenic approaches. 

Phagocyte.png
Phagocyte.png
Phagocyte.png

The Impact of Myeloid Cells in Disease

Myeloid Tx is applying more than 100 years of myeloid biology to build cutting edge platforms that target and reprogram myeloid cells.

Myeloid cells are the conductor of the immune system. They are the front lines of defense against disease, responsible for choreographing downstream immune responses.

 

Myeloid cells are versatile with effector functions capable of killing cancer cells. Our first-in-class platform harnesses the innate abilities of myeloid cells to engulf cancer cells, produce anti-tumor agents, promote anti-tumor adaptive immunity and alter the tumor microenvironment – and ultimately kill cancer.